QuidelOrtho Corp Dossier - Source-backed chat

QuidelOrtho Corp

QDELNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)0.80

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.38Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $711.8M

Enterprise Value $3.3B

Shares Outstanding 68.4M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

QuidelOrtho is navigating a transitional phase marked by near-term headwinds, including a significantly weaker respiratory season, pricing uncertainties in China, and high leverage. However, the company's core non-respiratory business remains resilient, and its multi-year Optimization Plan is expected to drive structural cost savings. The strategic acquisition of LEX Diagnostics and its ultra-fast LEX VELO PCR platform provides a strong long-term catalyst in point-of-care molecular diagnostics. Given the current valuation and execution risks, a Hold recommendation is warranted until margin expansion and cash flow improvements materialize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.00

Mean target$14.67

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$12.0015%

Prolonged pricing pressure from China's NHSA guidelines, integration delays with LEX Diagnostics, and persistent high interest expenses on its $2.69 billion debt load lead to further margin compression and covenant tightness.

Base CaseCentral scenario

$14.6760%

Matches the consensus mean

QuidelOrtho achieves the low end of its revised 2026 guidance, with revenues stabilizing around $2.70 billion and adjusted EBITDA margins reaching 23%. The wind-down of the U.S. donor screening business is completed, and free cash flow turns positive in the second half of 2026.

Bull CaseUpside scenario

$20.0025%

Rapid commercial adoption of the LEX VELO platform, faster-than-expected realization of the $50 million Optimization Plan savings, and a strong rebound in the 2026-2027 respiratory season drive significant margin expansion and debt paydown.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

High percentage of recurring revenue (>90%) supported by long-term laboratory contracts.
Strategic expansion into ultra-fast point-of-care molecular diagnostics via the LEX Diagnostics acquisition.
Robust multi-year Optimization Plan targeting $50 million in net cost savings by 2027.

Key Investment Risks

High leverage with $2.69 billion in total borrowings and elevated interest expenses.
Pricing and volume headwinds in China due to proposed NHSA reimbursement rate reductions.
High volatility and seasonal dependence of the respiratory testing business.

Thesis Invalidation Triggers

Failure to achieve positive free cash flow of $100 million to $120 million for the full year 2026.
Significant delays or commercial failure of the LEX VELO system launch in the U.S.
Deterioration of debt leverage ratios leading to credit covenant breaches.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.